Skip to main content

deferasirox (Exjade®)

 

Following a full submission

AWMSG advice

Status: Recommended

Deferasirox (Exjade®) is recommended for use within NHS Wales for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. It is also recommended for the treatment of chronic iron overload due to blood transfusions when desferrioxamine (DFO) therapy is contraindicated or inadequate in the following patient groups: - in patients with other anaemias, - in patients aged 2 to 5 years, - in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells). Deferasirox (Exjade®) is not suitable for shared care within NHS Wales.

 Final Recommendation: deferasirox (Exjade) 105 (PDF, 244Kb)

Medicine details

Medicine name deferasirox (Exjade®)
Formulation dispersible tablet
Reference number 105
Indication

Treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. Treatment of chronic iron overload due to blood transfusions when desferrioxamine therapy is contraindicated or inadequate in the following patient groups: patients with other anaemias; patients aged 2 to 5 years; patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells)

Company Novartis Pharmaceuticals UK Ltd
BNF chapter Nutrition & blood
Submission type Full
Status Recommended
Advice number 0808
NMG meeting date 14/05/2008
AWMSG meeting date 13/06/2008
Ratification by Welsh Government 17/07/2008
Date of issue 18/07/2008
Follow AWTTC: